DMRA Stock — Damora Therapeutics Inc.: Cash, EV, Pipeline

Share price

$22.59

Market cap

$1,394.6M

Cash

$540.5M

Enterprise value

$854.1M

Balance sheet

Cash	$540.5M
Debt	$0.0M
Net cash	$540.5M
Enterprise value	$854.1M
Basic shares	61.7M shares
Fully diluted shares	97.6M shares
Fully diluted market cap	$2,204.9M
Cash per share	$8.76

Cash figures as of 2026-06-30. Database snapshot: 2026-09-21.

Price history

Loading DMRA daily closes…

Loading price history…

Pipeline assets

DMR-001

Phase 1 · Active Modality: monoclonal antibody (subcutaneous)

Target mutCALR

Partnerships Paragon Therapeutics: option exercised Dec 8, 2025; exclusive license under negotiation; $1.25M research initiation fee; up to $22M milestones per product ($2.5M on first Phase 1 dosing); low-to-mid single-digit royalties; annual Paramora warrants (1% fully diluted)

Indications

Essential thrombocythemia (ET) (Phase 1)
Myelofibrosis (MF) (Phase 1)

Catalysts

— beginning mid-2027
— mid-2028

Status note Lead candidate; anti-mutCALR monoclonal antibody. Phase 1/1b trial in ET/MF recently initiated (health authority approval in first country); expansion cohorts planned next year.

DMR-002

Preclinical · Active

Target mutCALR

Partnerships Paragon Therapeutics: option exercised Apr 28, 2026; same economic terms as DMR-001

Indications

MPN (mutCALR-driven) (Preclinical)

Catalysts

— second half of 2026

Status note Second anti-mutCALR candidate. First regulatory submission planned 2H 2026.

DMR-003

Preclinical · Active Modality: bispecific T cell engager

Target mutCALR / CD3

Partnerships Paragon Therapeutics: option available, not yet exercised; same economic terms

Indications

MPN (mutCALR-driven) (Preclinical)

Catalysts

— 2027

Status note Bispecific CD3 x anti-mutCALR T cell engager. Paragon option not yet exercised; IND/CTA planned 2027.

GB3226

Stage not disclosed · Active Modality: small molecule

Target ENL-YEATS / FLT3

Indications

Acute myeloid leukemia (AML) (Stage not disclosed)

Status note Legacy asset. Deprioritized in Mar 2026 portfolio review as company focuses on mutCALR portfolio; company intends to explore partnerships or collaborations to advance it. Not explicitly discontinued.

GB1211

Stage not disclosed · Active

Target galectin-3

Indications

not disclosed (Stage not disclosed)

Status note Legacy galectin-3 inhibitor candidate; deprioritized Mar 2026; company intends to explore partnerships. Limited disclosure in excerpts.

GB2064

Stage not disclosed · Active

Target LOXL-2

Indications

not disclosed (Stage not disclosed)

Status note Legacy LOXL-2 inhibitor candidate; deprioritized Mar 2026; company intends to explore partnerships. Limited disclosure in excerpts.

Per-asset detail extracted from the 10-Q filed 2026-08-10. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.

No lead program on file for this company.

No active ClinicalTrials.gov trials matched to this company as sponsor or collaborator.

Institutional holders

Fund	Shares	Q/Q change	% of portfolio	Filing
Braidwell LP	1,620,377	+725,531	1.56%	2026-08-14
Ikarian Capital	335,710	no change	1.43%	2026-08-14
ADAR1 Capital Management	280,000	+1,000	0.34%	2026-08-14

Institutional holder positions from 13F filings. Q/Q change is vs the prior quarter's filing; % of portfolio is the fund's own reported portfolio weight.

DMRA — Damora Therapeutics Inc.

Balance sheet

Price history

Pipeline assets

Institutional holders